IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

COZZOLINO, MARIO GENNARO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 24.465
NA - Nord America 13.354
AS - Asia 6.634
SA - Sud America 492
OC - Oceania 133
AF - Africa 113
Continente sconosciuto - Info sul continente non disponibili 41
Totale 45.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.933
GB - Regno Unito 12.336
IT - Italia 3.965
CN - Cina 3.002
DE - Germania 2.489
SE - Svezia 1.498
FR - Francia 817
IE - Irlanda 774
IN - India 763
TR - Turchia 650
KR - Corea 536
UA - Ucraina 465
SG - Singapore 442
RU - Federazione Russa 399
FI - Finlandia 361
EU - Europa 333
NL - Olanda 294
JP - Giappone 276
CA - Canada 241
VN - Vietnam 201
GR - Grecia 173
DK - Danimarca 158
BR - Brasile 151
CO - Colombia 149
ES - Italia 140
HK - Hong Kong 139
ID - Indonesia 139
MX - Messico 130
TW - Taiwan 122
AU - Australia 107
BE - Belgio 103
CH - Svizzera 84
NO - Norvegia 74
TH - Thailandia 71
PL - Polonia 59
IR - Iran 58
AR - Argentina 56
RO - Romania 54
AT - Austria 45
PT - Portogallo 43
PE - Perù 40
CL - Cile 39
EC - Ecuador 34
IL - Israele 34
EG - Egitto 32
SA - Arabia Saudita 30
PH - Filippine 25
HU - Ungheria 24
PK - Pakistan 23
MY - Malesia 22
CZ - Repubblica Ceca 21
NZ - Nuova Zelanda 21
NG - Nigeria 19
NI - Nicaragua 17
RS - Serbia 16
ZA - Sudafrica 16
CY - Cipro 12
HN - Honduras 12
VE - Venezuela 12
BG - Bulgaria 10
BH - Bahrain 9
LB - Libano 9
LT - Lituania 9
SK - Slovacchia (Repubblica Slovacca) 9
GT - Guatemala 8
HR - Croazia 8
MA - Marocco 8
TN - Tunisia 8
BO - Bolivia 7
NP - Nepal 7
QA - Qatar 7
SC - Seychelles 7
SI - Slovenia 7
SY - Repubblica araba siriana 7
AE - Emirati Arabi Uniti 6
IQ - Iraq 6
AL - Albania 5
AP - ???statistics.table.value.countryCode.AP??? 5
BA - Bosnia-Erzegovina 5
CR - Costa Rica 5
KE - Kenya 5
LK - Sri Lanka 5
LV - Lettonia 5
MK - Macedonia 5
MM - Myanmar 5
MD - Moldavia 4
SD - Sudan 4
UY - Uruguay 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
FJ - Figi 3
MO - Macao, regione amministrativa speciale della Cina 3
OM - Oman 3
AM - Armenia 2
BD - Bangladesh 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
GE - Georgia 2
Totale 45.498
Salva come PNG Salva come JPEG
Città #
Southend 11.703
Chandler 1.317
Seattle 1.099
Milan 1.079
Fairfield 943
Princeton 900
Wilmington 787
Dublin 768
Ashburn 673
Beijing 551
Woodbridge 513
Houston 493
Ann Arbor 440
Cambridge 348
Nanjing 345
Mountain View 323
Redwood City 322
Jacksonville 313
Des Moines 312
Redmond 303
Munich 302
Bengaluru 274
Dearborn 271
Hanover 258
Boardman 230
Singapore 188
Rome 172
Andover 165
Somerville 165
Berlin 164
Sakarya 161
Frankfurt am Main 154
Phoenix 150
Shanghai 141
Sunnyvale 136
Athens 119
Bogotá 119
Toronto 112
Serra 109
Jinan 108
Dong Ket 103
Shenyang 103
New York 100
Changsha 99
Eitensheim 98
Istanbul 96
Hangzhou 95
Hebei 93
Guangzhou 92
Seoul 91
Tianjin 91
Helsinki 88
San Diego 87
Nanchang 85
Brussels 77
Turin 67
Bologna 66
Hong Kong 63
Nürnberg 62
Zhengzhou 61
Bühl 59
Tokyo 59
Taipei 55
London 50
Hamburg 48
Central District 45
Chengdu 45
Jiaxing 40
Kiez 39
Palermo 39
Stavanger 39
Verona 39
Jersey City 38
Ottawa 38
Bangkok 36
Chicago 36
Padova 35
Lima 34
Madrid 34
Roxbury 34
Kunming 33
Los Angeles 33
Guayaquil 30
Hefei 30
Naples 30
Pune 30
São Paulo 29
Florence 28
Fuzhou 28
Mumbai 28
Buenos Aires 27
Groningen 27
Silver Spring 26
Wuhan 26
Kent 25
Nuremberg 25
Leawood 24
Warsaw 24
Duncan 23
Haikou 23
Totale 30.138
Salva come PNG Salva come JPEG
Nome #
Type-5 cardiorenal syndrome (CRS-5): an up to date 582
Gli inibitori della Neprilisina nei pazienti affetti da Malattia Renale Cronica e Sindrome Cardio-Renale 562
Pathogenesis of secondary hyperparathyroidism 538
Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? 519
Iperfosfatemia in dialisi: la scelta del chelante 492
I nuovi Anti-Coagulanti Orali (NOAC) : cosa deve sapere un Nefrologo = New oral anticoagulants (NOAC) in nephrology 473
Malattia renale cronica e sindrome coronarica acuta : il ruolo della troponina = Troponins and chronic kidney disease 447
Terapia anticoagulante in pazienti con fibrillazione atriale in dialisi : fra il rischio di emorragia e la calcificazione vascolare 432
The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy 373
1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor 360
Anticoagulanti orali non Vitamina K dipendenti (NOACs) nei pazienti affetti da malattia renale cronica e fibrillazione atriale non valvolare = NOACs and Chronic kidney disease 323
Chelanti del fosforo a base di ferro : quali nuovi vantaggi? = Iron-based Phosphate Binders for ESRD Patients 301
Calcium-sensing receptor and calcium kidney stones 286
The calciotropic hormones PTH and vitamin D : from bone to blood vessels 264
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis : study design and baseline characteristics of the IMPACT SHPT study 257
Vitamin D receptor activation and prevention of arterial ageing [Reprint of] 254
Cardiac valve calcification : an immutable pathologic finding in chronic kidney disease? 249
Management of calcium refilling post - parathyroidectomy in end-stage renal disease 241
Ruolo della vitamina D nei pazienti con malattia renale cronica 240
Nuove acquisizioni nella patogenesi dell'iperparatiroidismo secondario = New insights in the pathogenesis of secondary hyperparathyroidism 237
Sevelamer use, vitamin K levels, vascular calcifications and vertebral fractures in hemodialysis patients: results from the VIKI study 231
Clinical significance of FGF-23 measurement in dialysis patients 228
Le alterazioni metaboliche del paziente nefropatico 222
VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey 221
1,25-Dihydroxyvitamin D downregulation of TGFα/EGFR expression and growth signaling: A mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure 215
Lanthanum Prevents High Phosphate-Induced Vascular Calcification by Preserving Vascular Smooth Muscle Lineage Markers 213
The effect of paricalcitol on vascular calcification and cardiovascular disease in uremia : beyond PTH control 210
Magnesium : a renewed player of vascular ageing in diabetic CKD patients? 208
Prevenzione delle calcificazioni extrascheletriche nel paziente uremico 206
Retarding chronic kidney disease (CKD) progression : a practical nutritional approach for non-dialysis CKD 204
Treatment of secondary hyperparathyroidism : the clinical utility of etelcalcetide 203
SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA 200
Effetti sulla funzione renale dei trattamenti antipertensivi associati 199
Nuovi scenari nell’iperparatiroidismo secondario: etelcalcetide : Position Paper dei Nefrologi lombardi [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy] 196
A multidisciplinary review of the science of vitamin D receptor activation 195
The key role of phosphate on vascular calcification 191
Nutritional Therapy, Phosphate Control and Renal Protection 190
Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy 187
End-stage renal disease costs for patients new to hemodialysis in Italy: The FARO-2 Study 184
The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification 184
Work ability and health status in dialysis patients 183
L’iperuricemia cronica con e senza deposito di urato 181
Pratica clinica per la diagnostica delle aritmie cardiache in pazienti in terapia renale sostitutiva: dati di una survey lombarda 175
Facial changes in adult uremic patients on chronic dialysis: possible role of hyperparathyroidism 173
Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients 171
Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD), coinvolgimento cardiovascolare e prognosi 168
Effetti cardioprotettivi della vitamina D nei pazienti con malattia renale cronica allo stadio 3-5 non in dialisi 167
La calcificazione vascolare nel paziente con insufficienza renale cronica 167
Collaborator EVOLVE Trial Investigators per l'articolo: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, New England Journal of Medicine 2012; 367:2482-2494 December 27, 2012 167
Vitamin K in Chronic Kidney Disease 167
Importance of vitamin D receptor activation in clinical practise 165
CKD-MBD : an endless story 165
The beneficial impact of vitamin D treatment in CKD patients : what's next? 164
Pathophysiology of calcium and phosphate metabolism impairment in Chronic Kidney Disease 163
Atherosclerotic Renovascular Disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH) 162
Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification 162
Vitamin D : something new under the sun 162
A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia 161
The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats 161
Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder 161
End Stage Renal Disease (ESRD) and Employability : an emerging occupational problem 160
Calcifying circulating cells: an uncharted area in the setting of vascular calcification in CKD patients 160
Extended-release calcifediol in stage 3-4 chronic kidney disease : a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D 157
Vascular calcification in chronic kidney disease : an update 156
Where is the link between mineral bone markers and cardiovascular disease in CKD? 156
Evaluation of renal function in elderly patients : performance of creatinine-based formulae versus the isotopic method using 99mTc-diethylene triamine pentaacetic acid 153
Ivabradine, heart failure and chronic kidney disease 153
Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment 152
Which Outcome in Chronic Kidney Disease-Mineral and Bone Disorder Patients? 151
Procedure in sala dialisi durante l’emergenza Covid-19 150
Prevenzione e trattamento dell’iperparatiroidismo secondario nel paziente con malattia renale cronica allo stadio 3-5 non in dialisi 149
Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats 149
Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure 149
The bone-vasculature-axis interaction: new insights into the pathogenesis of vascular calcification 147
Vitamin D: physiology and pathophysiology 147
Vitamin D therapy : an update. Vitamin D metabolites and/or analogs : which D for which Patient? 147
Treatment of hyperparathyroidism-why is it crucial to control serum phosphate? 145
Management of secondary hyperparathyroidism in uremic patients : the role of the new vitamin D analogs 144
Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease 144
La vitamina D nei pazienti con malattia renale cronica 144
Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis) : a case series 144
Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease 143
Which vitamin D in CKD-MBD? The time of burning questions 143
Vascular calcification in chronic kidney disease : a changing scenario 142
M Gene polymorphism and serum fetuin-A (AHSG) in haemodialysis (HD) patients 141
What would we like to know, and what do we not know about fibroblast growth factor 23? 141
Acute Kidney Injury, Type - 3 cardiorenal syndrome, Biomarkers, Renal Replacement Therapy 141
How to avoid and manage a pneumothorax 140
Unsuccessful application of taurolidine in the treatment of fungal peritonitis in peritoneal dialysis 140
Acute tubulo-interstitial nephritis requiring dialysis associated with intermittent rifampicin use : case report 140
Single-center open-label randomized study of anemia management improvement in ESRD patients with secondary hyperparathyroidism 140
Correction of metabolic acidosis improves insulin resistance in chronic kidney disease 140
Preventive measures and new pharmacological approaches of calcium and phosphate disorders 139
Anticoagulation in dialysis patients with central venous catheters: a word of caution 139
Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study 137
Anticoagulanti orali non vitamina K dipendenti (NOACs) nei pazienti affetti da malattia renale cronica e fibrillazione atriale non valvolare 137
A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease 136
Restoring the physiology of vitamin d receptor activation and the concept of selectivity 136
Gene polymorphisms and serum fetuin-A (AHSG) levels in haemodialisys (HD) patients 135
Vitamin D Metabolites and/or Analogs : Which D for Which Patient? 135
Totale 20.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.984
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.984
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019246 0 0 0 0 0 0 0 0 0 0 0 246
2019/20206.743 946 149 195 731 559 542 903 576 713 682 370 377
2020/20216.989 542 806 493 394 673 566 361 386 672 541 1.083 472
2021/20226.168 646 340 425 414 479 480 612 352 514 526 391 989
2022/20236.436 827 442 531 671 752 1.237 218 373 653 118 401 213
2023/20244.323 258 413 440 371 894 355 230 262 153 394 535 18
Totale 48.276